Basket cover image
15 handpicked stocks

Self-Care & Confidence

Invest in the companies behind the powerful daily rituals that millions can't live without. These carefully selected beauty and skincare stocks blend established global leaders with innovative disruptors, all benefiting from famously loyal customers who drive consistent, recurring revenue.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at June 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

EL

Estée Lauder Companies Inc.

EL

Current price

$89.87

As a global powerhouse, it owns an extensive portfolio of iconic skincare, makeup, and fragrance brands with immense customer loyalty.

ULTA

ULTA Salon, Cosmetics & Fragrance, Inc.

ULTA

Current price

$516.55

This company is a leading one-stop-shop beauty retailer, offering a vast range of products from mass-market to prestige brands.

ELF

E.L.F. Beauty, Inc.

ELF

Current price

$119.83

Known for its viral marketing, this brand offers trendy, vegan, and cruelty-free cosmetics at an accessible price point.

About This Group of Stocks

1

Our Expert Thinking

This collection captures the resilient beauty and skincare market where customer loyalty drives repeat purchases. We've balanced dividend-paying global icons with high-growth challengers disrupting the industry, positioning you to benefit from the growing integration of wellness and self-care into daily routines.

2

What You Need to Know

These companies benefit from the cultural shift toward viewing beauty as essential to overall wellness. The sector's strength comes from brand loyalty that creates reliable revenue streams, while social media's ability to drive viral product demand provides additional growth potential for innovative players.

3

Why These Stocks

We've handpicked companies across the entire beauty ecosystem—from global luxury houses and specialty retailers to innovative treatment developers and technology providers. This diversification helps capture different aspects of the beauty market while balancing established players with emerging disruptors.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+92.49%

Group Performance Snapshot

92.49%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 92.49% over the next year.

9 of 15

Stocks Rated Buy by Analysts

9 of 15 assets in this group are rated Buy by professional analysts.

2.3%

Group Growth

This group averaged a 2.3% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

Beauty's Recession-Resistant Edge

Even in tough times, consumers remain loyal to their favorite beauty products. This "lipstick effect" means beauty brands often maintain sales when other industries struggle.

📱

Social Media's Sales Magic

TikTok and Instagram can make beauty products go viral overnight, creating unprecedented demand. Companies mastering this digital landscape can see explosive growth almost instantly.

🌱

The Clean Beauty Revolution

Consumers are increasingly demanding sustainable, cruelty-free products with transparent ingredients. Brands leading this shift are capturing an enthusiastic, growing market willing to pay premium prices.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Orphan Drug Moats: Leaders In Rare Disease

Orphan Drug Moats: Leaders In Rare Disease

The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.

View stocks
Nvidia's China Chip Pivot

Nvidia's China Chip Pivot

Nvidia is developing a new, compliant AI chip for China, aiming to recapture market share lost to U.S. export controls. This strategic pivot creates a ripple effect, potentially benefiting the entire semiconductor supply chain that supports the production and deployment of this advanced hardware.

View stocks
Navigating The Autonomous Driving Shakeout

Navigating The Autonomous Driving Shakeout

A class-action lawsuit against Tesla regarding its Full Self-Driving claims puts the company's marketing and technology under intense scrutiny. This legal challenge could boost demand for competing autonomous driving technologies, creating opportunities for companies that supply advanced sensors and software.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.